Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis

Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Herpetic Keratitis Amino Acid Metabolism, Inborn Errors Congenital, Hereditary, and Neonatal Diseases and Abnormalities Corneal Diseases DNA Virus Infections Eye Diseases Eye Infections Eye Infections, Viral Genetic Diseases, Inborn Herpes Simplex Herpesviridae Infections Infections Keratitis Keratitis, Herpetic Metabolic Diseases Metabolism, Inborn Errors Mitochondrial Diseases Multiple Acyl Coenzyme A Dehydrogenase Deficiency Nutritional and Metabolic Diseases Virus Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Al-Azhar university

Damietta, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with herpetic keratitis

Exclusion criteria

Patients with known allergies to ganciclovir or acyclovir
Severe ocular surface disease
Those who have previously received antiviral therapy for herpetic keratitis within the last month

Treatment and study plan

Acyclovir 400 MG

Drug

Acyclovir is used to treat infections caused by certain types of viruses.

Ganciclovir (GCV)

Drug

Ganciclovir is an anti-viral drug

Primary outcomes

Corneal healing

Time frame: At 4 and 6 weeks

Heling of the keratitis

Secondary outcomes

Sie effects

Time frame: at 4 and 6 weeks

Measuring the percentage of the side effects of the drugs

Sponsors and collaborators

Lead sponsor

Al-Azhar University

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2024
First posted: Jan 3, 2025
Registry last updated: Jan 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed